Ginkgo Bioworks DNA Business Combination, Contingent Consideration, Change in Range of Outcomes, Liability, Maximum, Increase (Decrease)
Business Combination, Contingent Consideration, Change in Range of Outcomes, Liability, Maximum, Increase (Decrease) at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease)?
- Ginkgo Bioworks (DNA) reported business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease) of $0 in Q1 2026.
- How has Ginkgo Bioworks's business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease) changed year-over-year?
- Ginkgo Bioworks's business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease) decreased by 100.0% year-over-year, from $1.3M to $0.
- What does business combination, contingent consideration, change in range of outcomes, liability, maximum, increase (decrease) mean?
- Reflects adjustments to the estimated liability for future payments owed to sellers of acquired businesses based on performance milestones. Changes in this amount indicate whether the acquired entities are over- or under-performing relative to initial expectations. It serves as a key indicator of the success of M&A integration strategies.